|
Indian Journal of Medical Sciences
Medknow Publications on behalf of Indian Journal of Medical Sciences Trust
ISSN: 0019-5359 EISSN: 1998-3654
Vol. 59, Num. 12, 2005, pp. 546-555
|
Indian Journal of Medical Sciences, Vol. 59, No. 12, December, 2005, pp. 546-555
Practitioners section
Attention deficit hyperactivity disorder: A review for family physicians
Karande Sunil
Learning Disability Clinic, Division of Pediatric
Neurology, Department of Pediatrics, Lokmanya Tilak Municipal Medical
College and General Hospital, Sion, Mumbai, India
Correspondence Address: Dr. S. Karende, Learning Disability Clinic, Division
of
Pediatric Neurology, Department of Pediatrics, Lokmanya Tilak Municipal Medical
College
and General Hospital, Sion, Mumbai- 400 022, India, E-mail: karandesunil@yahoo.com
Code Number: ms05085
Abstract Attention deficit hyperactivity disorder (ADHD) is a chronic behavioral disorder characterized by persistent hyperactivity, impulsivity, and inattention that impairs educational achievement and/or social functioning. Its diagnosis is made by ascertaining whether the child's specific behaviors meet the diagnostic and statistical manual of mental disorders-IV-revised criteria. Its etiology is still unclear but recent studies suggest that genetics plays a major role in conferring susceptibility. Comorbidity with psychiatric disorders such as anxiety disorder, depression, oppositional defiant disorder and conduct disorder; and with specific learning disability is not uncommon. Although medication works well in most cases of ADHD, optimal treatment requires integrated medical and behavioral treatment. Methylphenidate (MPH) and atomoxetine are the two drugs being currently prescribed and their efficacy in decreasing the symptoms of ADHD is well documented. Pyschoeducational interventions in school can help increase the successful functioning of affected children and improve their academic performance. Almost half of affected children continue to show significant symptoms of the disorder into adolescence and young adulthood. The family physician can play an important role in detecting this condition early, coordinating its assessment and treatment, counseling the parents and classroom teacher, and monitoring the child's academic and psychosocial progress on a long-term basis.
Keywords: Attention deficit hyperactivity disorder, Family physicians, Primary care
For over 100 years it has been documented that some children can have excessive and impairing hyperactivity, impulsivity, and inattention.[1] In 1902, the English pediatrician George Still presented a series of three lectures to the Royal Society of Medicine describing 43 children from his clinical practice that were often resistant to discipline, who showed little inhibitory volition, had serious problems with sustained attention and could not learn from the consequences of their actions.[1] He proposed that these significant behavioral problems were due to an underlying neurological deficit and not caused by the environment.[1]
However, it was not till 1968 that the diagnostic and statistical manual of mental disorders (DSM) of the American Psychiatric Association first named this clinical disorder as hyperkinetic impulse disorder (DSM-II).[2] As newer clinical research emerged, the name changed to attention deficit disorder (DSM-III) in 1980, and eventually to attention deficit hyperactivity disorder (ADHD) (DSM-IV) in 1994.[3],[4]
Diagnosis of ADHD
Family physicians should initiate an evaluation for ADHD when a child presents with symptoms that include academic underachievement and failure, disruptive classroom behavior, inattentiveness, poor self-esteem, or problems with establishing or maintaining social relationships.[5] The
diagnosis of ADHD is based on clinical findings and is made by ascertaining
whether the child′s specific behaviors meet the DSM-IV-R criteria
[Table - 1].[7] These criteria define three subtypes of ADHD: (1) ADHD primarily of the inattentive type (ADHD/I); (2) ADHD primarily of the hyperactive-impulsive type (ADHD/HI); and, (3) ADHD, combined type (ADHD/C).[6]
A child meets the diagnostic criteria for ADHD by documentation of:
(1) presence of at least six of the nine behaviors described in the inattentive
domain (ADHD/I), or, at least six of the nine behaviors described in
the hyperactive/impulsive domain (ADHD/HI), or six of the nine behaviors
described in both domains (ADHD/C), and these behaviors should be occurring ′′often′′ and to a degree that is maladaptive and inconsistent with the child′s
developmental level [Table - 1]; (2) presence of these behaviors in two
or more settings (for example, at home and at school) for at least past
6 months; (3) presence of some symptoms of ADHD before 7 years of age
(history from parents); (4) clear evidence of clinically significant
impairment in academic or social functioning, or in both; (5) these symptoms
not occurring exclusively during the course of a pervasive developmental
disorder, schizophrenia, or another psychotic disorder, and not better
accounted for by another mental disorder (for example, a mood disorder
or an anxiety disorder).[6]
Family physicians should obtain the evidence regarding the core symptoms of ADHD directly from parents and the classroom teacher.[7] Cranial CT/MRI scan, electroencephalogram, and blood tests (e.g., thyroid hormone levels, lead levels) are not necessary for diagnosing ADHD.[7] However, audiometric and ophthalmic examinations should be done to rule out associated hearing and visual deficits, as they are common causes of poor school performance.
Prevalence of attention deficit hyperactivity disorder
Attention deficit hyperactivity disorder is one of the most common
behavioral disorders of childhood. Data from Western countries indicate
that 6.8% (range 8-12%) of school-going children have ADHD: 3.2% have ADHD-I, 0.6% have ADHD-HI, and 2.9% have
ADHD-C.[7],[8] Overall,
boys are affected three times more often than girls, but girls are more
likely than boys to have the ADHD-I subtype.[7],[8]
There is no data available from India of prevalence rates of ADHD among
elementary school-going children in the general population. However,
recent studies from Chandigarh and Kolkata have reported that 8.1 and
15.5% of children referred to the child guidance clinic, respectively,
were diagnosed as having ADHD.[9],[10]
What causes ADHD?
There is no one single unified theory that explains the etiology of ADHD.
Recent functional MRI brain studies indicate that the disorder may be
caused by atypical functioning in the frontal lobes, basal ganglia, corpus
callosum, and cerebellar vermis.[11],[12] Pharmacological
studies have also implicated dysregulation of frontal-sub cortical-cerebellar
catecholaminergic circuits (dopamine and norepinephrine neurotransmitter
systems) in the pathophysiology of the disorder.[13] Family
studies have provided strong evidence that genetics plays a major role
in conferring susceptibility to ADHD. [14],[15],[16] Studies
have indicated that low-birth weight and psychosocial adversity (for
example, severe parental discord, low-social class, foster placement)
are predisposing risk factors for ADHD.[17],[18] Also,
babies born to mothers who consume alcohol or smoke during pregnancy
are at risk for ADHD.[19],[20]
Comorbid conditions and their diagnosis
Family physicians should be aware that between 18% and 35% of
children with ADHD have one or more associated psychiatric disorders
such as anxiety disorder, depression, oppositional defiant disorder (ODD),
and conduct disorder (CD).[21],[22] Although
the family physician may not always be in a position to make a precise
diagnosis of these coexisting conditions, evidence for most of them can
be easily detected.[5] For
example, a family history of anxiety disorders coupled with a patient
history characterized by frequent fears and difficulties with separation
from caregivers may be suggestive of an anxiety disorder.[5] Frequent
sadness and preference for isolated activities should alert the physician
to the presence of depressive symptoms.[5] ODD
includes persistent symptoms of ′negativistic, defiant, disobedient,
and hostile behaviors toward authority figures.′[6] The
diagnostic features of CD, a more severe condition, include ′a
repetitive and persistent pattern of behavior in which the basic rights
of others or major age-appropriate social norms or rules are violated.′[6] Preliminary
studies suggest that ODD and CD are more frequent in children with the
ADHD-HI and ADHD-C subtypes, while depression and anxiety disorder are
more frequent in children with the ADHD-I and ADHD-C subtypes.[7],[8]
The Child Behavior Checklist (CBCL) is a useful screening tool for the
identification of psychiatric comorbidity in children and adolescents
with ADHD in the primary care setting. [23],[24],[25] It
is an affordable pencil and paper test completed by the child′s
caregiver, requiring no administration by a physician. Use, scoring,
and pricing information are accessible at: http://www.aseba.org/.[23],[24],[25] Referral
to a child psychiatrist is necessary when screening suggests psychiatric
comorbidity.
Also, up to 15-20% of children with ADHD have associated specific
learning disability (SpLD) which is manifested by significant unexpected,
specific and persistent difficulties in the acquisition and use of efficient
reading (dyslexia), writing (dysgraphia) or mathematical (dyscalculia)
abilities despite conventional instruction, intact senses, normal
intelligence, proper motivation, and adequate socio-cultural opportunity.[26] Associated
SpLD adds to the academic underachievement and failure.[22] Referral
to a learning disability clinic is necessary when the academic difficulties
are suggestive of SpLD.[26] Psychoeducational
testing will be required to determine whether a discrepancy exists between
the child′s learning potential (intelligence quotient) and actual
academic progress (achievement test scores). The clinical psychologist
conducts the standard intelligence test viz. Wechsler intelligence
scale for children test to determine that the child′s intellectual functioning is normal. The special educator assesses the child′s academic achievement by administering a standard educational test (for example, wide range achievement test or curriculum-based test) to assess the child′s
performance in areas such as reading, spelling, written language, and
mathematics.[26] An academic
achievement of 2 years below the child′s actual school grade placement
or chronological age is considered diagnostic of SpLD.[26]
Recent data also indicates that girls with ADHD are less likely to have
any of this coexisting conditions.[27]
Importance of early diagnosis of ADHD
It is now well recognized that the presence of a child with ADHD
results in increased likelihood of disturbances to family and marital
functioning, disrupted parent-child relationships and increased levels
of parent stress, particularly when ADHD is comorbid with ODD or CD.[28] Even
parents of preschool children with ADHD may be under huge stress when
their child does not respond to ordinary parental requests and behavioral
advice.[29]
If ADHD remains undetected the child may experience academic failure,
rejection by peers, and develop low-self-esteem. [30],[31],[32],[33] Whereas
it was previously thought that all children eventually outgrow ADHD,
recent studies suggest that 30-60% of affected children continue
to show significant symptoms of the disorder into adolescence and young
adulthood. [30],[31],[32],[33]Adolescence
may bring about a reduction in the over activity but inattention, impulsiveness,
and inner restlessness remain resulting in academic, behavioral, and
social impairment. [30],[31],[32],[33] Among
individuals whose symptoms abate during adolescence, the outcome may
be similar to that of normal subjects in terms of social functioning,
and drug and alcohol use, although not academic achievement.[30],[31],[33] Adults
with persistent symptoms complete less formal schooling, have lower-status
jobs and have higher rates of antisocial personality.[30],[31],[33]
If ADHD with coexisting psychiatric conditions remains undetected the
prognosis is poorer. Adolescents with ADHD and coexisting depression
are at increased risk for suicide attempts.[34] Frequently,
children and adolescents with ADHD with persisting ODD later develop
symptoms of sufficient severity to qualify for a diagnosis of CD.[35] The
frequency of substance-use disorder, mostly not involving alcoholism,
is higher among adolescents and young adults with ADHD predominantly
among those with coexisting CD. [30],[31],[32]
Thus, it is important to identify ADHD early during childhood, rather
than when chronic poor school performance, or problems with strained
parent-child relationship or social functioning and their attendant emotional
sequelae ensue.
Management of ADHD
The three treatments that have been validated as being significantly
effective for ADHD are: (1) medication management, (2) behavioral therapy,
and (3) a combination of the two approaches.[36]
(1) Medication management of ADHD : To achieve amelioration of
the core ADHD symptoms, medication management is superior to behavioral
therapy.[36] MPH and atomoxetine
are the two drugs which are being currently prescribed and their efficacy
in decreasing the symptoms of ADHD is well documented. [36],[37],[38],[39],[40] Medications
are not recommended for use in children who are below 6 years of age. [36],[37],[38],[39],[40]
Most children with ADHD improve on the stimulant MPH and maintain their
improvement without intolerable adverse events. [36],[37],[38] MPH
is believed to act on central dopamine and norepinephrine pathways. [36],[37],[38] Short-acting
MPH is now available in our country. Its behavioral effects begin within
30 min of oral administration and last for 3-5 h. The daily dose should
be individualized by titration and careful monitoring and it ranges from
5 to 20 mg twice daily to three times daily. [36],[37],[38] Side
effects include anorexia, stomachache, headache, irritable mood, tics,
and sleep difficulties. These side effects, however, are usually mild
and responsive to dose adjustment and often abate with continuous use.
Continuous use has been associated in some children with slowing of physical
growth (approximately 1 cm/year during the first 1-3 years of treatment),
which is transient and of unclear cause. [36],[37],[38] In
Western countries, long-acting MPH is now available and it permits once-daily
administration (18-54 mg) and its behavioral effects last for 10-12 h.[38] Long-acting
MPH is used to ensure compliance in children who feel embarrassed to
take medication in school.[38]
Atomoxetine a nonstimulant highly selective noradrenaline reuptake inhibitor,
is a new drug, which represents an important advance in the pharmacological
management of ADHD. [38],[39],[40] Atomoxetine
demonstrates efficacy comparable to methylphenidate in the treatment
of ADHD. [38],[39],[40] Once-daily
dosing of atomoxetine has been shown to be effective in providing continuous
symptom relief. The starting dose is 0.5 mg/kg/day and increased after
4 days to 1.2-1.4 mg/kg/day. Its most commonly reported adverse effects
are transient and include dyspepsia, nausea, vomiting, decreased appetite,
and weight loss. [38],[39],[40]
In general, medication is best titrated against desirable effects such
as behavioral control, improved educational achievement and peer group
relations, and development of intolerable adverse effects.[38] Medication
can be discontinued on Sundays and school holidays. Also, periodic (yearly)
discontinuation for a brief period (for example, during summer vacations)
is often used to reaffirm the need for continuing medication.[38]
Additional pharmacological options include the antidepressants: bupropion
and desipramine; and the antihypertensives: clonidine and guanfacine.[38] But
the scientific base supporting the efficacy of these drugs is limited.[38] Another
stimulant drug, pemoline, although effective is no longer used because
of its potential to cause serious hepatotoxicity.[38]
(2) Behavioral therapy : Parents are taught by psychologists
or social workers to achieve consistent and positive interactions with
their affected child. They are taught how to reinforce positive behaviors
by praise or by using daily contingency charts (star or ′happy face′charts),
how to extinguish negative behaviors by active ignoring, and how to effectively
punish for intolerable behaviors.[41] Parent
training is the sole treatment for children with ADHD who are below 6
years of age.[42]
Simple pyschoeducational interventions at school such as seating the
child near the teacher to minimize classroom distractions, or assigning
a specific teacher to review daily assignments with the child have been
shown to be effective in improving the behavior and academic performance
of affected children.[43]
(3) Combined treatment : Optimal treatment of ADHD requires integrated
medical and behavioral (combined) treatment.[36] Although
combined treatment does not yield significantly greater benefits than
medication management for core ADHD symptoms, it helps reduce the total
daily required medication dose and the associated non-ADHD symptoms viz.
symptoms of anxiety and depression, and oppositional/aggressive behaviors;
and helps achieve positive functioning outcomes for peer interactions,
parent-child relations, and reading achievement.[36] Recent
research suggests that combined treatment may help prevent the development
of future psychiatric disorders.[36]
Management of associated SpLD
The cornerstone of treatment of SpLD is remedial education. The
child has to undergo remedial education sessions twice or thrice weekly
for a few years to achieve academic competence.[26],[44] The
child should also avail the required provisions (accommodations) to help
cope up in a regular mainstream school, e.g. exemption from spelling
mistakes, availing extra 30 min for all written tests, dropping a second
language and substituting it with work experience, dropping algebra and
geometry and substituting them with lower grade of mathematics, and work
experience.[26],[44]
Important role of family physician
Every family physician can facilitate early detection of ADHD by enquiring
during a consultation whether the child has problems in learning at school,
and specifically asking the parents whether they are concerned about
their child′s behavior in school, or at home.[7] The
family physician can play a crucial role in coordinating the assessment
(obtaining information of child′s behavior from parents and classroom
teacher) and treatment (prescribing ongoing medication once the patient
is stabilized, and ensuring compliance) of ADHD.[7] Those
familiar with its management can even initiate the medication management,
but will need to liaise with a child psychiatrist/developmental pediatrician
regarding any complications in treatment (for example, intolerable side
effects or treatment failure) or if comorbid conditions (ODD, CD, anxiety,
depression, SpLD) are suspected.[7]
It is well known that favorable outcome of ADHD is dependent on a supportive
home and school environment.[36] The
family physician can play an important role in counseling the parents
and classroom teacher of a child with ADHD about the need for medication,
psychoeducational interventions, analyze their feedback about the child′s specific target behaviors to titrate the medication dose, and monitor the child′s
academic progress on a long-term basis.
Parents of a child with ADHD may consult their family physician about
the utility of unconventional therapies such as cognitive treatments,
individual psychotherapy, play therapy, restrictive or supplemental diets,
mineral or amino acid supplements, megavitamins, herbal medicines, homeopathy,
allergy treatments, neurofeedback, and vestibular and sensorimotor integration
to treat their child′s disorder. None of these have proved to
be effective when subjected to double-blind controlled clinical trials. [45],[46],[47],[48],[49],[50] The
family physician can help parents become better-informed consumers.
To conclude, every family physician can play a crucial role in ensuring
that no child with ADHD loses out in life.
References
1. | Still GF. The Goulstonian lectures on some abnormal psychical conditions in children. Lancet 1902;1:1008-12, 1077-82, 1163-8. Back to cited text no. 1 |
2. | American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 2nd ed. Washington, DC: American Psychiatric Association; 1968. Back to cited text no. 2 |
3. | American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 3rd ed. Washington, DC: American Psychiatric Association; 1980. Back to cited text no. 3 |
4. | American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington, DC: American Psychiatric Association; 1994. Back to cited text no. 4 |
5. | American Academy of Pediatrics. Clinical practice guideline: diagnosis and evaluation of the child with attention-deficit/hyperactivity disorder. Pediatrics 2000;105:1158-70. Back to cited text no. 5 |
6. | American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed. rev. Washington, DC: American Psychiatric Association; 2000. Back to cited text no. 6 |
7. | Brown RT, Freeman WS, Perrin JM, Stein MT, Amler RW, Feldman HM, et al. Prevalence and assessment of attention-deficit/hyperactivity disorder in primary care settings. Pediatrics 2001;107:e43. Back to cited text no. 7 |
8. | Wolraich M, Hannah JN, Baumgaertel A, Pinnock TY, Feurer I. Examination of DSM-IV criteria for attention deficit/hyperactivity disorder in a county-wide sample. J Dev Behav Pediatr 1998;19:162-8. Back to cited text no. 8 |
9. | Malhi P, Singhi P. Spectrum of attention deficit hyperactivity disorders in children among referrals to psychology services. Indian Pediatr 2000;37:1256-60. Back to cited text no. 9 |
10. | Mukhopadhyay M, Misra S, Mitra T, Niyogi P. Attention deficit hyperactivity disorder. Indian J Pediatr 2003;70:789-92. Back to cited text no. 10 [PUBMED] [FULLTEXT] |
11. | Vaidya CJ, Austin G, Kirkorian G, Ridlehuber HW, Desmond JE, Glover GH, et al. Selective effects of methylphenidate in attention deficit hyperactivity disorder: a functional magnetic resonance study. Proc Natl Acad Sci U S A 1998;24;95:14494-9. Back to cited text no. 11 |
12. | Giedd JN, Blumenthal J, Molloy E, Castellanos FX. Brain imaging of attention deficit/hyperactivity disorder. Ann N Y Acad Sci 2001;931:33-49. Back to cited text no. 12 |
13. | Pliszka SR, McCracken JT, Maas JW. Catecholamines in attention-deficit hyperactivity disorder: current perspectives. J Am Acad Child Adolesc Psychiatry 1996;35:264-72. Back to cited text no. 13 |
14. | Waldman ID, Rowe DC, Abramowitz A, Kozel ST Mohr JH, Sherman SL, et al. Association and linkage of the dopamine transporter gene and attention-deficit hyperactivity disorder in children: heterogeneity owing to diagnostic subtype and severity. Am J Hum Genet 1998;63:1767-76. Back to cited text no. 14 |
15. | Barr CL, Wigg KG, Bloom S, Schachar R, Tannock R, Roberts W, et al. Further evidence from haplotype analysis for linkage of the dopamine D4 receptor gene and attention-deficit hyperactivity disorder. Am J Med Genet 2000;96:262-7. Back to cited text no. 15 |
16. | Bakker SC, van der Meulen EM, Buitelaar JK, Sandkuijl LA, Pauls DL, Monsuur AJ, et al. A whole-genome scan in 164 Dutch sib pairs with attention-deficit/hyperactivity disorder: suggestive evidence for linkage on chromosomes 7p and 15q. Am J Hum Genet 2003;72:1251-60. Back to cited text no. 16 |
17. | Mick E, Biederman J, Prince J, Fischer MJ, Faraone SV. Impact of low birth weight on attention-deficit hyperactivity disorder. J Dev Behav Pediatr 2002;23:16-22. Back to cited text no. 17 |
18. | Biederman J, Milberger S, Faraone SV, Kiely K, Guite J, Mick E, et al. Impact of adversity on functioning and comorbidity in children with attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1995;34:1495-503. Back to cited text no. 18 |
19. | Mick E, Biederman J, Faraone SV, Sayer J, Kleinman S. Case-control study of attention-deficit hyperactivity disorder and maternal smoking, alcohol use, and drug use during pregnancy. J Am Acad Child Adolesc Psychiatry 2002;41:378-85. Back to cited text no. 19 |
20. | Linnet KM, Dalsgaard S, Obel C, Wisborg K, Henriksen TB, Rodriguez A, et al. Maternal lifestyle factors in pregnancy risk of attention deficit hyperactivity disorder and associated behaviors: review of the current evidence. Am J Psychiatry 2003;160:1028-40. Back to cited text no. 20 |
21. | Pliszka SR. Patterns of psychiatric comorbidity with attention-deficit/hyperactivity disorder. Child Adolesc Psychiatr Clin N Am 2000;9:525-40, vii. Back to cited text no. 21 |
22. | Busch B, Biederman J, Cohen LG, Sayer JM, Monuteaux MC, Mick E, et al. Correlates of ADHD among children in pediatric and psychiatric clinics. Psychiatr Serv 2002;53:1103-11. Back to cited text no. 22 |
23. | Achenbach TM. Manual for the Child Behavior Checklist/4-18 and the 1991 Profile. Burlington, VT: University of Vermont, Department of Psychiatry; 1991. Back to cited text no. 23 |
24. | Biederman J, Faraone SV, Doyle A, Lehman BK, Kraus I, Perrin J, Tsuang MT. Convergence of the Child Behavior Checklist with structured interview-based psychiatric diagnoses of ADHD children with and without comorbidity. J Child Psychol Psychiatry 1993;34:1241-51. Back to cited text no. 24 |
25. | Biederman J, Monuteaux MC, Greene RW, Braaten E, Doyle AE, Faraone SV. Long- term stability of the Child Behavior Checklist in a clinical sample of youth with attention deficit hyperactivity disorder. J Clin Child Psychol 2001;30:492-502. Back to cited text no. 25 |
26. | Kulkarni M, Kalantre S, Upadhye S, Karande S, Ahuja S. Approach to learning disability. Indian J Pediatr 2001;68:539-46. Back to cited text no. 26 [PUBMED] [FULLTEXT] |
27. | Biederman J, Mick E, Faraone SV, Braaten E, Doyle A, Spencer T, et al. Influence of gender on attention deficit hyperactivity disorder in children referred to a psychiatric clinic. Am J Psychiatry 2002;159:36-42. Back to cited text no. 27 |
28. | Johnston C, Mash EJ. Families of children with attention-deficit/hyperactivity disorder: review and recommendations for future research. Clin Child Fam Psychol Rev 2001;4:183-207. Back to cited text no. 28 |
29. | DuPaul GJ, McGoey KE, Eckert TL, VanBrakle J. Preschool children with attention- deficit/hyperactivity disorder: impairments in behavioral, social, and school functioning. J Am Acad Child Adolesc Psychiatry 2001;40:508-15. Back to cited text no. 29 |
30. | Mannuzza S, Klein RG. Long-term prognosis in attention-deficit/hyperactivity disorder. Child Adolesc Psychiatr Clin N Am 2000;9:711-26. Back to cited text no. 30 |
31. | Mannuzza S, Klein RG, Bessler A, Malloy P, LaPadula M. Adult psychiatric status of hyperactive boys grown up. Am J Psychiatry 1998;155:493-8. Back to cited text no. 31 |
32. | Bagwell CL, Molina BS, Pelham WE Jr, Hoza B. Attention-deficit hyperactivity disorder and problems in peer relations: predictions from childhood to adolescence. J Am Acad Child Adolesc Psychiatry 2001;40:1285-92. Back to cited text no. 32 |
33. | Mannuzza S, Klein RG, Moulton JL 3rd. Persistence of attention deficit/hyperactivity disorder into adulthood: what have we learned from the prospective follow-up studies? J Atten Disord 2003;7:93-100. Back to cited text no. 33 |
34. | Brent DA, Perper JA, Goldstein CE, Kolko DJ, Zelenak JP Risk factors for adolescent suicide: a comparison of adolescent suicide victims with suicidal inpatients. Arch Gen Psychiatry 1988;45:581-8. Back to cited text no. 34 |
35. | Waxmonsky J. Assessment and treatment of attention deficit hyperactivity disorder in children with comorbid psychiatric illness. Curr Opin Pediatr 2003;15:476-82. Back to cited text no. 35 |
36. | The MTA Cooperative Group. A 14-month randomised clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 1999;56:1073-86. Back to cited text no. 36 |
37. | Schachter HM, Pham B, King J, Langford S, Moher D. How efficacious and safe is short-acting methylphenidate for the treatment of attention-deficit disorder in children and adolescents? A meta-analysis. CMAJ 2001;165:1475-88. Back to cited text no. 37 |
38. | Reeves G, Schweitzer J. Pharmacological management of attention-deficit hyperactivity disorder. Expert Opin Pharmacother 2004;5:1313-20. Back to cited text no. 38 |
39. | Kratochvil CJ, Vaughan BS, Harrington MJ, Burke WJ. Atomoxetine: a selective noradrenaline reuptake inhibitor for the treatment of attention-deficit/hyperactivity disorder. Expert Opin Pharmacother 2003;4:1165-74. Back to cited text no. 39 |
40. | Christman AK, Fermo JD, Markowitz JS. Atomoxetine, a novel treatment for attention-deficit-hyperactivity disorder. Pharmacotherapy 2004;24:1020-36. Back to cited text no. 40 |
41. | Pelham WE Jr, Fabiano GA. Behavior modification. Child Adolesc Psychiatr Clin N Am 2000;9:671-88, ix. Back to cited text no. 41 |
42. | Sonuga-Barke EJ, Daley D, Thompson M, Laver-Bradbury C, Weeks A. Parent-based therapies for preschool attention-deficit/hyperactivity disorder: a randomized, controlled trial with a community sample. J Am Acad Child Adolesc Psychiatry 2001;40:402-8. Back to cited text no. 42 |
43. | Hoffman JB, DuPaul GJ. Psychoeducational interventions for children and adolescents with attention-deficit/hyperactivity disorder. Child Adolesc Psychiatr Clin N Am 2000;9:647-61, ix. Back to cited text no. 43 |
44. | Dakin KE. Educational assessment and remediation of learning disabilities. Semin Neurol 1991; 11:42-9. Back to cited text no. 44 |
45. | Abikoff H, Gittelman R. Hyperactive children treated with stimulants: is cognitive training a useful adjunct? Arch Gen Psychiatry 1985;42:953-61. Back to cited text no. 45 |
46. | Wender EH. The food additive-free diet in the treatment of behavior disorders: a review. J Dev Behav Pediatr 1986;7:35-42. Back to cited text no. 46 |
47. | Pelham WE Jr, Wheeler T, Chronis A. Empirically supported psychosocial treatments for attention deficit hyperactivity disorder. J Clin Child Psychol 1998;27:190-205. Back to cited text no. 47 |
48. | Elia J, Ambrosini PJ, Rapoport JL. Treatment of attention-deficit hyperactivity disorder. N Engl J Med 1999;340:780-8. Back to cited text no. 48 |
49. | Voigt RG, Llorente AM, Jensen CL, Fraley JK, Berretta MC, Heird WC. A randomized, double-blind, placebo-controlled trial of docosahexaenoic acid supplementation in children with attention-deficit/hyperactivity disorder. J Pediatr 2001;139:189-96. Back to cited text no. 49 |
50. | Chan E. The role of complementary and alternative medicine in attention-deficit hyperactivity disorder. J Dev Behav Pediatr 2002;23 Suppl 1:S37-45. Back to cited text no. 50 |
Copyright 2005 - Indian Journal of Medical Sciences
The following images related to this document are available:
Photo images
[ms05085t1.jpg]
|